Innovation

Amplia announces second confirmed complete response in ACCENT trial June 19, 2025

Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer.

Race confirms safe and successful dosing of first patient in Phase 1 solid tumour trial June 19, 2025

Race Oncology (ASX:RAC) has announced the successful and safe combination dosing of the first patient with RC220 plus doxorubicin in its Phase 1 clinical trial in advanced solid tumour patients.

Orthocell says new study confirms superiority of Remplir over standard nerve repair technique June 19, 2025

Regenerative medicine company Orthocell (ASX:OCC) has announced interim results from a new study evaluating the impact of sutures on nerve regeneration and functional recovery in the surgical repair of severed peripheral nerves.

Imugene announces US patent allowance for onCARlytics June 19, 2025

Imugene (ASX:IMU) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application number that protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR-T cell therapies.

Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo June 19, 2025

CLINUVEL (ASX:CUV) has announced final results from its Phase 2 pilot study evaluating SCENESSE (afamelanotide) as a monotherapy in patients with the depigmentation disorder vitiligo.

'Go Healthy with Taiwan' invites submissions from Australian health innovators June 17, 2025

The global initiative aims to engage governments, institutions, enterprises, and organisations in submitting innovative proposals that integrate Taiwan’s home-grown health innovations.

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group June 17, 2025

James Graham, CEO of Recce Pharmaceuticals, said, “This facility marks a significant step in strengthening our capital position at a critical juncture."

Clarity enters manufacturing agreement for Cu-64 SAR-bisPSMA with SpectronRx June 17, 2025

Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has entered into a commercial manufacturing agreement with SpectronRx for the company's lead diagnostic product, 64Cu-SAR-bisPSMA.

New pathway for mRNA drug delivery shows shape of things to come June 17, 2025

Scientists working at RMIT University and Osaka University have discovered that the internal shape of tiny drug-delivery particles, known as lipid nanoparticles, has a significant impact on how well our cells absorb them.

Amplia says pathological complete response in patient from ACCENT trial June 17, 2025

Amplia Therapeutics (ASX:ATX) has announced important new data from its ongoing ACCENT clinical trial in pancreatic cancer.

Australian company secures FDA approval to progress development of CAR-T therapy June 17, 2025

The US FDA has approved an Investigational New Drug, enabling the Melbourne-based company Myrio to progress its lead product into human clinical trials.

Radium Capital unleashes $400m war chest for Australian innovators June 12, 2025

Radium Capital, Australia’s leader in R&D finance, has announced plans to lend $400 million to Australian innovators over the next 12 months.

Most Read

Amplia announces second confirmed complete response in ACCENT trial

Imugene announces US patent allowance for onCARlytics

Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo

Orthocell says new study confirms superiority of Remplir over standard nerve repair technique

Race confirms safe and successful dosing of first patient in Phase 1 solid tumour trial

New Stories

Amplia announces second confirmed complete response in ACCENT trial

Race confirms safe and successful dosing of first patient in Phase 1 solid tumour trial

Orthocell says new study confirms superiority of Remplir over standard nerve repair technique

Imugene announces US patent allowance for onCARlytics

Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo

'Go Healthy with Taiwan' invites submissions from Australian health innovators

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group

Sign In

Most Read

Amplia announces second confirmed complete response in ACCENT trial

Imugene announces US patent allowance for onCARlytics

Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo

Orthocell says new study confirms superiority of Remplir over standard nerve repair technique

Race confirms safe and successful dosing of first patient in Phase 1 solid tumour trial

Follow Us

New Stories

Amplia announces second confirmed complete response in ACCENT trial

Race confirms safe and successful dosing of first patient in Phase 1 solid tumour trial

Orthocell says new study confirms superiority of Remplir over standard nerve repair technique

Imugene announces US patent allowance for onCARlytics

Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo

'Go Healthy with Taiwan' invites submissions from Australian health innovators

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group